The Super Rich: Start from when the family business is about to go bankrupt!

Chapter 461 WPG0460: Want to make original research drugs? A compromise to get the best of both worlds! Black-hearted capitalists! Harvesting multiple times?
Two days later.

On October 20th, Wugengtian Pharmaceutical Group officially announced the acquisition of the [Rheumatism Project] led by Professor Xiong Yuanji.

Referring to the [Lupus Project] led by Professor Wei Zhenghong, the [Rheumatism Project] led by Professor Xiong Yuanji will also return to the Imperial Capital Union Medical College to continue research and development work.

However, the relevant R&D expenses will be borne by Wugengtian, and Wugengtian will also need to bear the relevant R&D site rental costs of the Imperial Capital Union Medical College.

An Wuyang went to the imperial capital in person to complete the final signing work.

After finishing the acquisition of the [Rheumatology Team], Professor Wei Zhenghong found An Wuyang.

"Mr. An, we have good news to tell you!" Professor Wei Zhenghong handed a brown paper file bag to An Wuyang.

When An Wuyang took it, he guessed the answer!

If nothing unexpected happens, the lupus remission drug should be developed successfully, right?

When An Wuyang opened the file bag and looked at the specific information, his guess was confirmed.
wrong!

This document only shows that the first phase clinical trial of a lupus-relieving drug performed well.

An Wuyang raised his eyebrows and asked, "Professor Wei, are you planning to make the lupus erythematosus relief agent into an original drug?"

Professor Wei Zhenghong responded hesitantly, "Our lupus erythematosus relief agent is indeed an original drug."

"Then what?" An Wuyang asked back.

"How many phases of clinical trials will be conducted next?" An Wuyang continued to ask.

"Although lupus remission drugs are not serious life-threatening diseases such as tumors, cardiovascular diseases and neurological diseases, we can skip the Phase 0 clinical trial and directly enter the Phase I clinical trial, but how long will it take us?" An Wuyang asked.

"Even if we ignore the final Phase IV clinical trial and only do Phases I, II and III clinical trials, it will still take at least five to seven years, right?" An Wuyang asked.

Most Phase I, II and III clinical trials last five to seven years.

This means that if lupus-relieving drugs are to be marketed as original drugs, even if they skip the approval process, they will still have to wait at least five to seven years.

Being safe and sound can wait!

But can other investors wait?
Professor Wei Zhenghong hesitated. She also knew that Phase I, II and III clinical trials would take an average of five to seven years, which was indeed a long time.

"Mr. An, is there any way to speed up the clinical trials?" Professor Wei Zhenghong asked.

"Why faster?" An Wuyang asked back.

"Professor Wei, you are also engaged in medical research and development. Don't you know that even if you work fast, it will take at least three years?" An Wuyang complained.

"Phase I clinical trials can be completed within a few months, and Phase II can also be completed within a few months. There is indeed room for maneuver," An Wuyang explained.

"But for the Phase III clinical trial, we will need a sample size of at least 300 and at most 3,000 subjects. No matter how we operate, it will take more than two years. Ultimately, the entire clinical trial process will be compressed to three years." An Wuyang sighed.

"I know you want to develop an original drug, but you also have to consider the investors' ideas," An Wuyang added.

Professor Wei Zhenghong remained silent.

An Wuyang added, "I have a compromise idea!"

Professor Wei Zhenghong immediately looked at An Wuyang, "Please speak, Mr. An."

"You should still follow the normal route of original drug research and development. The clinical trials should be conducted as clinical trials, but you should also come up with a version of the lupus erythematosus relief drug." An Wuyang explained.

"You can make the new version of lupus relief medicine into a health product or a herbal medicine, preferably a herbal medicine from a classic formula. This way we can bypass clinical trials." An Wuyang added.

More than ten years ago, bypassing clinical trials by using classic herbal prescriptions became a popular practice.

What An Wuyang is doing now is just repeating what his predecessors did.

After all, other people can do this, so why can't An Wuyang do the same?

More importantly, lupus relief medicine is a genuine and effective medicine, not a copycat medicine that borrows "classic herbal medicine recipes".

An Wuyang would like to say, at the risk of being criticized by the industry, that most of the herbal medicines that appear to be classic prescriptions cannot withstand in-depth investigation.

It’s a pity that the benefits are so great that it is tacitly accepted.

After listening to An Wuyang's proposal for compromise, Professor Wei Zhenghong did not refuse.

"Then let's make an oral liquid version of the medicine and add the classic recipe of Angelica Blood-Replenishing Decoction. What do you think, Mr. An?" Professor Wei Zhenghong asked An Wuyang for his advice.

"I have no objection. The main thing is, after doing this, can the efficacy of the medicine be fully preserved?" An Wuyang asked.

Professor Wei Zhenghong answered affirmatively, "No problem!"

"Then do this first, and then try the efficacy of the medicine." An Wuyang ordered.

"We'll try to get it done within three days, is that ok?" An Wuyang asked.

Professor Wei Zhenghong assured, "Don't worry, it will be done within three days!"

After An Wuyang finished his conversation with Professor Wei Zhenghong, he contacted the relevant shareholders of Hongyuan Pharmaceutical one by one, preparing to treat the shareholders to a meal and explain the matter.

……

Around five in the evening.

National Guesthouse, Fangfei Garden.

All shareholders of Hongyuan Pharmaceutical, including the team represented by Chen Hongzhi and Gu Mingyue from the Didu Circle, and the team represented by Li Shiyu from the Shengqing Circle, were invited.

In the state banquet restaurant, Li Shiyu first asked, "Brother Wuyang, is there anything that you are calling everyone for today?"

Chen Hongzhi and Gu Mingyue also looked at An Wuyang.

An Wuyang took out the file bag from his briefcase, then pulled out a stack of documents from the bag and placed them on the revolving table.

"Everyone take a copy and look at the information first." An Wuyang signaled everyone to check the information.

Everyone was not polite and each of them took a copy of the information.

These documents have been filed with paper clips for easy access.

Chen Hongzhi quickly checked the file information. After a moment, he exclaimed, "Fuck! It actually worked?"

Li Shiyu also agreed in amazement, "The lupus erythematosus project we invested in was successfully developed?"

Gu Mingyue was also shocked. She had originally intended to invest in An Wuyang in order to improve his favorability, but in the end, the lupus project was successful?
Yang Yuxin is also very concerned about this matter. If the lupus erythematosus relief drug is successfully developed, even if she only has 0.5% of the shares, it will become an important trump card in her hand.

An Wuyang answered affirmatively, "From the current point of view, the lupus erythematosus relief drug can be considered a success!"

"According to Professor Wei's experiment, you all know that Professor Wei is a patient with lupus erythematosus, right?" An Wuyang asked. Everyone nodded.

Gu Mingyue answered affirmatively, "We all know that we have investigated Professor Wei's information and we admire Professor Wei very much."

"Now there is a problem before us," An Wuyang added.

"Professor Wei wants to make an original drug and turn the lupus remission drug into an original drug, which can eventually enter the global market through formal channels." An Wuyang explained.

"I have given a compromise." An Wuyang repeated the compromise solution.

"I would like to ask for everyone's opinion. Does anyone have any ideas?" An Wuyang asked.

Everyone looked at each other, wondering whether An Wuyang really wanted to ask for their opinions or was just being polite?
After all, the equity and voting rights of Hongyuan Pharmaceutical Research and Development Company are divided into two parts, the AB share model!
Wu Geng Tian indeed only has 40% of the shares, but it has more than 90% of the voting rights. If An Wuyang insists on having his own way, they have no way to stop him.

Lin Qianli spoke first, "I think it is very appropriate for Brother Wuyang to split the plan into two parts. It not only meets the needs of listing and cashing out, but also ensures the route of original research drugs."

This is nonsense!

But nonsense often also represents an attitude, and Lin Qianli's attitude is to support An Wuyang.

Li Shiyu seconded the proposal and said, "I think the compromise proposed by Brother Wuyang is very good. I support it!"

Gu Mingyue guessed An Wuyang's real purpose. An Wuyang was not asking about the pros and cons of their compromise at all.

Because under the current circumstances, the compromise solution proposed by An Wuyang is already the best way to deal with it.

After all, a compromise is the epitome of 'having it all'!

Didn’t Lin Qianli analyze it all?

Therefore, Gu Mingyue could be 100% sure that this was not the purpose of An Wuyang calling them together today.

"Could this guy be trying to allocate quotas, discuss pricing, and divide sales areas?" Gu Mingyue guessed.

As everyone expressed their support for An Wuyang's compromise, the state banquet dishes were served one by one. While eating, everyone praised Professor Wei Zhenghong's team.

When people praise Professor Wei Zhenghong's team at this time, they are actually bragging about themselves, because they think it is because of their good vision that they chose a good project.

I have to say, these people are thinking too much, right?

When more than half of the state banquet dishes had been served, the speed at which people were tasting slowed down.

An Wuyang began to bring up the things that really needed to be discussed.

Just as Gu Mingyue guessed, An Wuyang needed to discuss prices and sales areas with everyone.

As for quota
This is such an easy solution!
The quota is matched according to the share of equity.

For example, if Wugengtian holds 40% of the shares, it will take 40% of the quota.

Yang Yuxin only has 0.5% of the shares, so naturally she only has 0.5% of the quota.

"The document contains the cost price of lupus remission drugs. Let's discuss what price would be appropriate for us to sell it at?" An Wuyang asked.

There are two core elements in the formula of lupus relief potion: the [lupus inhibition ingredient] and the [vitality recovery factor].

Each dose of lupus relief medicine contains 3 grams of [inhibitory ingredients], and the total cost is 30 yuan.

It also contains 20 mg of [vitality recovery factor].

Wu Gengtian offered Hongyuan Pharmaceutical Research and Development Company a price of 10 Xia Guoyuan per gram for the vitality recovery factor.

The cost price of 20 mg of vitality recovery factor is 2000 yuan.

The core raw material cost of each lupus erythematosus relief drug is as high as 2030 yuan, if you add the auxiliary materials and outer packaging cost of 2 yuan, and the production cost of 0.1 yuan.
The total cost is 2032.1 yuan.

All I can say is that the cost of lupus relief drugs is relatively high!
Fortunately, the lupus relief medicine is very effective and only one dose is needed to take effect, thereby suppressing the three types of cutaneous lupus erythematosus: acute, subacute, and chronic.

Once cutaneous lupus erythematosus is suppressed, as long as lifestyle habits are regular and the immune system functions stably, the effect will most likely be maintained for a long time.

Lupus erythematosus will not relapse unless the immune system declines again or other diseases are contracted, resulting in a decline in body function.

In short, a lupus remission medication is a temporary solution, but it is an effective long-term solution.

Lupus erythematosus relief medicine is different from Shuxin Pills.

Shuxin Pills need to be taken every month, while the interval for taking lupus remission medication varies from person to person.

Perhaps someone will use one dose and never have a relapse for the rest of their life.

Some people may relapse in just two or three days.

For example, a patient took lupus remission drugs to suppress cutaneous lupus erythematosus, and then played mahjong all night for two consecutive days, which caused immune system dysfunction and body function decline, and then induced lupus erythematosus.

Isn't this suicidal?

You can't blame the medicine for being ineffective, right?

Chen Hongzhi asked, "I remember that the number of lupus patients worldwide seems to be only 5 million to 6 million?"

An Wuyang answered affirmatively, "The data available is roughly this number. After all, some backward areas are not counted. The number of lupus patients in our country is approximately between 80 and 100 million."

Chen Hongzhi sighed and said, "This market is a bit small!"

"And our medicine is a little too effective. Can we make it into something similar to Shuxin Pills, so that the efficacy can last for a month and then need to be consumed continuously every month?" Chen Hongzhi suggested.

An Wuyang was too tired to complain.

This guy is really a typical black-hearted capitalist, huh?
It is not good if the drug is too effective. It must be reduced to ensure continuous consumption every month in order to earn long-term and lasting profits.

Li Shiyu seconded, "Brother Hongzhi's proposal is very good! I support it!"

Only Yang Yuxin of Ping An Xingtian Group is seriously considering the appropriate selling price.

The cost price is just over 2,000 yuan. Although the efficacy of the medicine is very good, it may cause recurring problems if you have bad living habits.

So maybe there could be a buyback offer?
For example, the price of the first portion is very high, so that the first batch of customers with financial conditions can be steadily harvested.

In addition, for those who have unhealthy living habits, which lead to recurring attacks of lupus erythematosus, we can set a preferential repurchase price and even establish a membership repurchase system.

For example, by setting up an annual membership system, you can get the corresponding membership price, and then buy lupus relief drugs again at a relatively favorable price.

Such a sales plan can also prevent people whose illnesses recur in the short term from losing their temper and giving up treatment.

(End of this chapter)